SEC Form 4 · accession 0000904454-26-000394
uniQure N.V. · QURE
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Walid Abi-Saab
Officer — Chief Medical Officer
Period of report
Jun 30, 2026
Accepted (ET)
Jul 2, 2026 · 4:59 pm EDT
Rule 10b5-1 plan
yes — trade under a plan
Issuer CIK
0001590560
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Ordinary Shares | Jun 30, 2026 | M | 10,000 | $5.59 | A | 178,235 | D | |
| Ordinary SharesF2 | Jun 30, 2026 | S | 10,000 | $46.46 | D | 168,235 | D | |
| Ordinary SharesF3 | Jun 30, 2026 | S | 20,000 | $46.40 | D | 148,235 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F4 | $5.59 | Jun 30, 2026 | M | 10,000 | D | — | Mar 1, 2034 | Ordinary Shares | 10,000 | 50,500 | D |
Explanation of responses
- F1The transactions reported herein were effected pursuant to a sales plan adopted by the Reporting Person on September 26, 2025 and intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934.
- F2The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $46.19 to $46.97. The Reporting Person undertakes to provide to the Issuer, any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in the footnote.
- F3The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $46.24 to $46.80. The Reporting Person undertakes to provide to the Issuer, any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in the footnote.
- F4The Stock Option was granted on March 1, 2024 and vested 25% on the first anniversary of the date of grant, and vests 6.25% quarterly thereafter until fully vested.